Evidence map›Paper›PMID 21510932›Full record

ReviewExperimental cell research2011

Development of anti-CD20 therapy for multiple sclerosis.

Beatrix Bartok, Gregg J Silverman

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Experimental cell research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. B-cell targeted therapeutics in clinical development.Arthritis research & therapy · 2013
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Beatrix BartokDepartment of Medicine, UC San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Gregg J Silverman
University of California, San Diego · US

Funding

B CELL SUPERANTIGENS AND IMMUNE REGULATIONR01AI040305 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SILVERMAN, GREGG JOSHUA · 1998 to 2008
$2.4M
Cell Death and Antibody-Mediated Protection from AutoimmunityR01AI068063 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SILVERMAN, GREGG JOSHUA · 2006 to 2010
$2.1M
Lupus and the inhibitory dual receptor hypothesisR01AI090118 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SILVERMAN, GREGG JOSHUA · 2010 to 2014
$2.0M
NIAID NIH HHS R01 AI040305NIAID NIH HHS R01 AI068063NIAID NIH HHS R01 AI090118
6 · The paper itself

Abstract

The therapeutic utility of the targeting of B lymphocytes is currently being evaluated in a range of autoimmune diseases that include multiple sclerosis (MS). For MS, even though intrathecal immunoglobulin production is a hallmark of multiple sclerosis (MS), T cells have long been considered as the main effectors of pathogenesis. Recognition of the roles of autoreactive B cells has changed this conventional view of the disease and also provided a rationale for studies of anti-CD20 therapy in MS. Recent trials suggest that this approach may provide clinical benefits in some MS patients that equal or surpass currently approved approaches, yet not all patients may benefit. In this review we provide an overview on recent progress on these trials.

Indexed as

AnimalsAntibodiesAntibodies, Monoclonal, Murine-DerivedAntigens, CD20B-LymphocytesClinical Trials as TopicHumansMultiple SclerosisRituximabAntibodiesAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Rituximab

Identifiers

PMID21510932
PMCPMC3266104
OpenAlexW2116071356

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.